Forazapadin not checked

Satellos Bioscience, Inc. · SAT-3247

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SAT-3247 is a selective AAK1 inhibitor for oral tablet administration which promotes functional rescue of asymmetric satellite cell division, resulting in the robust production of muscle progenitor cells, subsequent improvement in muscle regeneration, and enhanced muscle function.”In the company’s words, NCT07287189 on ClinicalTrials.gov
Tested for
Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies, Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
Main trialPhase 2
“Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.”In the company’s words, NCT07287189 on ClinicalTrials.gov
Other names
SAT-3247

Other drugs for Duchenne Muscular Dystrophy

All 23 drugs for Duchenne Muscular Dystrophy

Coming up3

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 31 Mar 2027 Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Phase 2Recruiting 30 Sep 2027 An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
Phase 2Not yet recruiting 30 Dec 2028 A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Forazapadin

Following is part of Solo: you see every change to Forazapadin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in